Citadel Advisors
STRO icon

Citadel Advisors’s Sutro Biopharma STRO Stock Holding History

Citadel Advisors’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,780
Closed -$12.7K – 14050
2025
Q2 		$12.7K Buy
1,780
+1,700
+2,125% +$13.9K ﹤0.01% 12176
2025
Q1 		$520 Buy
+80
New +$1.26K ﹤0.01% 14252
2024
Q4 		– Sell
-210
Closed -$7.27K – 15357
2024
Q3 		$7.27K Buy
210
+190
+950% +$7.45K ﹤0.01% 13371
2024
Q2 		$586 Sell
20
-760
-97% -$30.1K ﹤0.01% 13958
2024
Q1 		$44.1K Buy
780
+610
+359% +$26.9K ﹤0.01% 12295
2023
Q4 		$7.29K Buy
170
+70
+70% +$2.22K ﹤0.01% 13295
2023
Q3 		$3.47K Sell
100
-210
-68% -$9.15K ﹤0.01% 13580
2023
Q2 		$14.4K Buy
310
+260
+520% +$12.9K ﹤0.01% 13003
2023
Q1 		$2.31K Sell
50
-350
-88% -$22.2K ﹤0.01% 14167
2022
Q4 		$32.3K Buy
+400
New +$27.8K ﹤0.01% 12646
2021
Q3 		– Sell
-1,300
Closed -$242K – 14617
2021
Q2 		$242K Sell
1,300
-350
-21% -$68.5K ﹤0.01% 11770
2021
Q1 		$376K Buy
+1,650
New +$392K ﹤0.01% 10332

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors's STRO Position: Q1 2026 in Review

Citadel Advisors increased its Sutro Biopharma (STRO) stake by 266% in Q1 2026, buying an estimated $1.54M and bringing the position to 117,537 shares worth $2.93M. The position accounts for ﹤0.01% of the portfolio, ranked #5313.

Citadel Advisors first reported a position in STRO in Q3 2018 and has held it in 29 quarters since. The position peaked at $28.1M in Q4 2020. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Citadel Advisors held 117,537 shares of Sutro Biopharma worth $2.93M as of Q1 2026.
  • Citadel Advisors bought 85,452 Sutro Biopharma shares in Q1 2026, an estimated $1.54M.
  • Sutro Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5313 holding.
  • Citadel Advisors first reported a position in Sutro Biopharma in Q3 2018 and has held it in 29 quarters since.
  • Citadel Advisors's Sutro Biopharma position peaked at $28.1M in Q4 2020.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.